The global anti-malarial drugs market was valued at around US$ 948.5 Million at the end of 2021. The market is projected to register a 4.8% CAGR and top a valuation of US$ 1515.8 Million by 2032.
Due to increased research for novel medications and new combination therapies the anti-malarial drugs market is set to experience significant revenue growth in the coming times.
Malaria is a contagious illness that spreads when a female Anopheles mosquito bites a host, allowing parasites to enter the body. Fever, exhaustion, nausea, and headaches are additional symptoms brought on by the destruction of red blood cells by merozoites, which also proliferate inside them. Antimalarial drugs are those that are used to treat and ward against malaria infections. Several drugs are available in the market for the treatment of malarial infection such as quinine, chloroquine, proguanil, mefloquine, and pyrimethamine.
| Attributes | Details |
| Anti-Malarial Drugs Market Value in 2021 | US$ 948.5 Million |
| Anti-Malarial Drugs Market Value in 2032 | US$ 1515.8 Million |
| Anti-Malarial Drugs Market CAGR (2022 to 2032) | 4.8% |
The high prevalence of malaria in affected nations increased public awareness due to government initiatives to reduce the prevalence rate of malaria by conducting various campaigns for spreading awareness about the prevention of malaria, and increased research for the development of novel drugs and new combination therapies, among other things, are the factors that are driving the growth of anti-malarial drugs market.
One of the aspects driving the market's development is the rise in the incidence of traveler’s malaria. Numerous tourists from around the world visit malaria-infected nations each year, which is predicted to raise the risk of disease.
Strong efforts made by various regional and international governments and regulating agencies, including the USA Food and Drug Administration (FDA), to reduce the prevalence of the malarial disease worldwide are also seen to be a major driver of the market for anti-malarial drugs. Other key elements fueling the expansion of the global market for anti-malarial drugs are the presence of significant players, improved Research and Development facilities, and healthcare expenditure.
The anti-malarial drugs market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
Africa is the leading region in the global anti-malarial drugs market owing to the high prevalence of malarial infection in various nations in the region and various healthcare facilities provided by global health agencies.
Increasing regulatory approval of the medications and the presence of major pharmaceutical companies are predicted to contribute to the lucrative development of the anti-malarial drug market in East Asia in the coming years.
The South American region is also predicted to show lucrative growth due to increasing awareness regarding the use of anti-malaria drugs for the early diagnosis of malarial disease.
Alvizia Healthcare Pvt. Ltd., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Merck & Co., Inc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories), Zydus Cadila, Lincoln Pharmaceuticals, Strides Pharma Science, Glenmark Pharmaceuticals, Alliance Pharmaceuticals.
| Report Attributes | Details |
| Growth Rate | CAGR of 4.8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered |
|
| Region Covered |
|
| Key Countries Profiled |
|
| Key Players |
|
| Customization | Available Upon Request |
The global anti-malarial drugs market is anticipated to register a CAGR of 4.8% during the forecast period.
The global anti-malarial drugs market is projected to be about US$ 1515.8 Million by the end of the year 2032.
Explore Similar Insights
Anti-Malarial drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
